Business Wire

Verimatrix Application Shielding Technology Wins CSI Magazine Award

30.9.2020 08:15:00 EEST | Business Wire | Press release

Share

Regulatory News:

Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that ProtectMyApp, an application shielding solution for mobile app developers, was named Best Cybersecurity Service in the 18th Annual CSI Magazine Awards. Winners were announced during a virtual broadcast on September 18.

Verimatrix’s application shielding technology is routinely recognized for its ability to streamline the implementation of code protection while still providing the most robust security possible for mobile app developers.

“It’s crucial to vigorously secure the actual mobile applications that have become such a vital part of our industry,” said Goran Nastic, editor of CSI Magazine. “Delivering increasingly valuable content, mobile apps and their developers can be armed with latest application shielding technologies that result in self-defending apps. Congratulations to Verimatrix for being named the winner of this year’s Best Cybersecurity Service.”

“Verimatrix’s uniquely powerful mix of expertise in both video security and code protection results in application shielding technologies that are unmatched in the industry,” said Asaf Ashkenazi, COO at Verimatrix. “We are honored that CSI Magazine named Verimatrix a winner in this year’s Best Cybersecurity Service category. We remain committed to offering intelligent, automated software security that ensures apps remain fully trusted by their users and unappealing for cybercriminals to mess with in the first place.”

For more information on application shielding options, visit https://www.verimatrix.com/solutions/code-protection.

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com.

About CSI Magazine Awards
Celebrating excellence and achievement in the broadcast, video, OTT and IoT sectors, the CSI (Cable and Satellite International Magazine) Awards stand as one of the most prestigious and competitive technology honors in the industry. Founded in 2003, the awards are designed to recognize and reward innovation and excellence in the cable, satellite, broadcast, IPTV, telco, broadband/OTT video, mobile TV and associated sectors. Visit www.csimagazine.com/awards/index.php.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations Contact:
Richard Vacher Detournière
General Manager & Chief Financial Officer
+33 (0)4 42 905 905
finance@verimatrix.com

Media Contact:
Matthew Zintel
+1 281 444 1590
matthew.zintel@zintelpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 16:00:00 EEST | Press release

Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in

Gurobi Launches Intelligence Hub to Deliver AI-Guided Workflows Across the Optimization Lifecycle7.7.2026 16:00:00 EEST | Press release

Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of the Gurobi Intelligence Hub, the new home for Gurobi’s AI-powered optimization agents. The Intelligence Hub is designed to help users build, understand, troubleshoot, and interact with optimization models more effectively. Together, the Hub’s specialized agents leverage generative AI to guide users through workflows across the optimization lifecycle, creating new opportunities to make optimization more accessible, intuitive, and valuable for a broader range of users. The Modeler combines guided workflows with Gurobi’s optimization expertise to help users move from business problem to production-quality optimization model. Through an iterative process that helps refine requirements, validate assumptions, and develop acceptance tests, the Modeler gives users confidence that their model accurately reflects the intended business problem.The Explainer helps users interpret model instances

SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement7.7.2026 16:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets. As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactions. Having already enabled the issuance and distribution of tokenized funds, SS&C is now extending its innovation roadmap to support the next stage of the digital i

Quaise Energy Raises $134 Million in Initial Close of Series B to Build World’s First Superhot Geothermal Power Plant7.7.2026 15:01:00 EEST | Press release

Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the first close of its Series B financing, raising $134 million with additional equity and debt capital expected to close imminently. The round was led by Prelude Ventures, with strategic investments from JERA and Idemitsu, two of Japan's largest energy companies. Nearly all existing investors, including Safar Partners, participated in the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707844187/en/ The proceeds from Series B will fund Project Obsidian, the world’s first commercial superhot geothermal power plant, and the continued development and commercialization of Quaise's millimeter wave drilling system towards depths in excess of 5 km. Project-level equity and debt financing is concurrently being raised as the company advances toward first revenues secured by yet-undisclosed commercial off-take partners. The Series

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development7.7.2026 15:00:00 EEST | Press release

Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of light-chain mispairing and providing a robust molecular foundation for subsequent BsADC development. By bringing together the complementary capabilities of Biocytogen and Whitehawk, the collaboration aims to identify BsADC candidates with differentiated targeting profiles and therapeutic potential. “W

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye